Dutch Atherosclerosis Society

Prof. dr. J.J.P. Kastelein, chairman advisory board 

Condensed curriculum vitae

Professor John J.P. Kastelein received his medical degree from the University of Amsterdam in 1980 and was subsequently trained in internal medicine at the Academic Medical Centre of the foresaid University. Prof Kastelein was trained in lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of prof M.R. Hayden. Upon his return to the Netherlands he founded the Lipid Research Clinic at the Academic Medical Centre in Amsterdam, currently serving as a tertiary referral centre for over five thousand patients each year. Prof Kastelein's major research interests lie in the molecular basis of hypertriglyceridemia, hypercholesterolemia and low HDL-cholesterol. Prof Kastelein has set up a foundation for the active identification of patients with classical Familial Hypercholesterolemia in the Netherlands, for which he holds the medical directorship. His current position is professor of Medicine and director of the Lipid Research Group of the department of Vascular Medicine at the University of Amsterdam, where he is co-chairman. In 1997 and 1998 he served a visiting Professorship at the Center for Molecular Medicine and Therapeutics at the University of British Columbia, Vancouver, Canada. Prof Kastelein has published over 200 publications in peer reviewed journals and was awarded an Established Investigatorship of the Dutch Heart Foundation. He also serves on a number of executive and steering committees of lipid lowering intervention trials.

Biography

Name: Kastelein, Johannes Jacob Pieter

Place of birth: Haarlemmermeer

Date of birth: 13 January, 1954

Nationality: Dutch

Marital status: Married; two children

Education

1980 University of Amsterdam Medical Degree

1980-1982 Resident Internal Medicine Military Hospital Dr. A. Matthijsen, Utrecht

1982 Chief Resident, Haemodialysis Unit, Military Hospital Dr. A. Matthijsen, Utrecht

1982-1985 Resident, Internal Medicine, Slotervaart Training Hospital, Amsterdam

1983-1985 Postgraduate Courses and Exams: Haemostasis and Thrombosis Clinical Pharmacology Epidemiology and Biostatistics Immunology Respiration and Circulation

1985 Boerhaave Courses: Renovascular Hypertension Left Ventricular Hypertrophy Electrocardiography

1985 Medical Council of Physicians and Surgeons, Canada Evaluation Examination for Canadian Medical Degree, Paris, France

1985-1986 Resident, Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam

1986-1987 Research Fellow, Department of Laboratory Medicine, University of British Columbia, Vancouver

1987 Clinical Fellow, Department of Medical Genetics, University of British Columbia, Vancouver

1987-1988 Junior Scientist, Lipidologist, Lipid Research Clinic, University of British Columbia, Vancouver

1989 Young Scientist Award. International Society for Thrombosis and Haemostasis, XIIth Congress, Tokyo, Japan,

1991 Academic Thesis The Molecular Basis of Inherited Disorders of Lipoprotein Metabolism (with honours)

1997 - 1998 Visiting Professor, University of British Columbia, Dept. Of Medical Genetics, Vancouver, Canada.

1999 Co-Chairman Department of Vascular Medicine, Academic Medical Center, University of Amsterdam

2000 Established Investigator Netherlands Heart Foundation

2002 Professor of Medicine; Strategic Chair of Cardiovascular Genetics, University of Amsterdam

Functions

1999 - Co-Chairman, Department of Vascular Medicine, Academic Medical Center of the University of Amsterdam.

Established Investigator of the Netherlands Heart Foundation.

Professor of Medicine, Academic Medical Center, University of Amsterdam.

Director, Lipid Research Group and Lipid Research Clinic at the Academic Medical Center, University of Amsterdam.

Board, Dutch National Foundation for the Identification of Familial Hypercholesterolemia (StOEH).

Chairman, National Scientific Committee on Familial Hypercholesterolemia.

Lead Consultant Europe, Xenon Genetics Inc.

Co-founder, Amsterdam Molecular Therapeutics Inc.

Co-founder, CardiAlpha Clinical Network Europe

Treasurer and Chairman, Dutch Atherosclerosis Society

Board, Vascular Research Network

Board, Lipid Clinic Network

Member of the Committee Familial Hypercholesterolemia, Health Council of the Netherlands

Chairman, Dutch Atherosclerosis Society Advisory Board (2008)


Memberships

Dutch Lipoprotein Club

Royal Society for Medicine and Physics,

Amsterdam Council for Basic Science of the American Heart Association Scientific Advisory Board,

Dutch Heart Foundation

European Atherosclerosis Society Steering Committee

TNT trial Steering Committee

IDEAL trial Steering Committee

METEOR trial Steering Committee

DISCOVERY trial

PhD project present

Drs. E. van Aalst Genetics of FH

Drs. R. Bisoendial HDL metabolism

Drs. M. Genen Late effects of childhood cancer

Drs. G. de Grooth CETP inhibition

Drs. G.K. Hovingh HDL genetics

Drs. A.C.M. Jansen Genetic determinants of risk in FH patients

Drs. M. Nieuwdorp Type I diabetes

Drs. R. Ozsoy Dyslipidemia in renal failure

Drs. J. Rodenburg FH in Children

Drs. R. Sankatsing HDL-metabolism

Drs. R. Singaraja ATP binding cassette AI

Drs. A. Wiegman; FH in children.

Drs. S. van Wissen ApoAIMilano, a new treatment modality

PhD project past

Dr.Ir. J.C. Defesche The molecular basis and treatment of familial hypercholesterolemia 29 January 1993

Dr. P.J. Lansberg The molecular basis and treatment of familial hypercholesterolemia 29 January 1993

Dr. T. Bruin Human Lipoprotein lipase; molecular genetics & structure function analysis. 9 March 1994 (with honours)

Dr. H.C. Knipscheer The pharmacological treatment of primary hyperlipidemia. 21 December 1994

Dr. S.M. Bijvoet The molecular biology of familial chylomicronemia. 21 December 1994

Dr. Y.Y. van der Hoek Lipoprotein(a): structure/function analysis and metabolism. 7 September 1995

Dr. J.A. Kuivenhoven Genetic factors contributing to HDL cholesterol levels. 3 December 1996

Dr. B.E. Groenemeijer Genetic factors contributing to dyslipidemia and coronary artery disease. 3 June 1997

Dr. M.E. Wittekoek Familial Hypercholesterolemia. Molecular genetics and clinical expression. 4 December 1998

Dr. S.N. Pimstone Genetic and environmental determinants of dyslipidemia and coronary artery disease. 17 December 1998

Mr.Dr. M.J. Van Dam Dyslipidemia, diagnosis and treatment. 26 oktober 2001

Dr. M.A.W. Umans-Eckenhausen Genetic insights, clinical efficacy and practical implications of genetic screeting for Familial Hypercholesterolemia. 28 november 2002

Dr. P.R.W. de Sauvage Nolting Genetics and therapy of familial hypercholesterolemia. 11 december 2002

Dr. S de Jongh Familial Hypercholesterolemia in childhood. 13 december 2002

Dr. M.D. Trip The spectrum of premature atherosclerosis: from single gene to complex genetic disorder. 19 december 2002

Publications
1983
1. Het koerierssyndroom. J. Geerling, J.J.P. Kastelein, D. Agenant. Ned. Tijdschr. Geneeskd. 1983; 127: 874?64.
1985
2. Urinary creatine: Biochemical indicator for evaluation of sickle cell crises. C. Beyer, L.W. Statius van Eps, J.J.P. Kastelein, D.P.M. Brandjes, W.M. Mairuhu, A. van den Ende. Clin. Chem. 1985; 31; 1232?1234.
1986
3. First trimester prenatal diagnosis for Huntington disease using DNA probes. M.R. Hayden, J.J.P. Kastelein, J. Hewitt, S. Langlois, R.D. Wilson, S. Fox, C.M. Hilbert, M. Bloch. Lancet 1987; I: 1284?85.
4. Insufficient evidence to invoke defects in or around the AI gene as the cause for familial hypoalphalipoproteinemia. M.R. Hayden, J.J.P. Kastelein, S. Langlois. Atherosclerosis 1987; 67: 271?72.
1988
5. A polymorphic DNA marker which represents a conserved expressed sequence in the region of the Huntington Disease gene. M.R. Hayden, J. Hewitt, J.J. Wasmutn, J.J.P. Kastelein, J. Haines, B. Smith, M. Conneally, C.M. Hilbert, S. Allard. Am. J. Hum. Genet. 1988; 42: 125?31.
6. Characterization of six partial deletions in the low?density lipoprotein (LDL) receptor gene causing familial hypercholesterolemia (FH). S. Langlois, J.J.P. Kastelein, M.R. Hayden. Am. J. Hum. Genet. 1988; 43: 60?68.
1989
7. A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency. S. Langlois, S. Deeb, J.J.P. Kastelein, J.D. Brunzell, M.R. Hayden. Proc. Natl. Acad. Sci. USA 1989;86:948?952.
8. Niertubulusfunctiestoornissen door azijnzuur. G.H.C. Schardijn, J.J.P. Kastelein, L.W. Statius van Eps. Ned. Tijdschr. Geneeskd. 1989;133:556-558.
1990
9. The gene causing familial hypoalphalipoprotenemia is not caused by a defect in the Apo AI?CIII?AIV gene cluster in a Spanish family. J.J.P. Kastelein, J.L. Haines, M.R. Hayden. Human. Genet. 1990; 84: 396?400.
10. A missense mutation at codon 188 of the human lipoprotein lipase gene causes lipoprotein lipase deficiency in persons of different ancestries. M.V. Monsalve, H. Henderson, G. Roederer, P. Julien, S. Deeb, J.J.P. Kastelein, L. Peritz, R. Devlin, T. Bruin, M.R.V. Murthy, C. Gagne. J.D. Brunzell, M.R. Hayden. J. Clin. Invest. 1990;86:728-734
1991
11. The prediction of the therapeutic response to cholesterol lowering drugs in an 11?year old boy with homozygous familial hypercholesterolemia. H.D. Bakker, P.P.M. Schilte, T. Bruin, M.C.L. Schaap, P.J. Lansberg and J.J.P. Kastelein. J. Inher. Metab. Dis. 1991:14;3.
12. De Low?Density Lipoprotein (LDL)?receptor. Caput Selectum. J.J.P. Kastelein, J.W. ten Cate. Ned. Tijdschr. Geneeskd. 1991;135:646-651.
13. High-Density Lipoproteine. J.J.P. Kastelein. Ned. Tijdschr. Klin. Chem. 1991;16:106-109.
14. Een patient met de homozygote vorm van Familiaire Hypercholesterolemie. J.W. Gorter, J.J.P. Kastelein, P.J. Lansberg, P.P.M. Schilte, H.D. Bakker. Ned. Tijdschr. Kindergeneesk. 1991;59:88-91.
15. The molecular defect causing fish eye disease: An amino acid exchange in lecithin: cholesterol acyltransferase (LCAT) leads to the selective loss of alpha?LCAT activity. H. Funke, A. von Eckardstein, P.H. Pritchard, J.J.P. Kastelein, J.J. Albers, C.C. Droste, G. Assmann. Proc. Natl. Acad. Sci. (USA) 1991;88:4855-4859.
16. HindIII-polymorphism in the LPL-gene detected by PCR. T. Bruin, P.W.A. Reymer, B.E. Groenemeyer, P.J. Talmud and J.J.P. Kastelein. Nucl. Acids. Res 1991;19:6346.
1992
17. Hemostase, Thrombose en Perifere Vaatziekten. A. Sturk, H.R. Büller, J.J.P. Kastelein, J.W. ten Cate. Hoofdstuk in Leerboek Interne Geneeskunde 1992, Eds. G.J. den Ottolander. 10e herziene druk. Bohn, Stafleu, van Loghum, Houten/Zeventer.
18. Two naturally occuring mutations at the first and second base of codon Asp156 in the proposed catalytic triad of human lipoprotein lipase - in vivo evidence that Asp156 is essential for catalysis. Y. Ma, S. Tuzgöl, T. Bruin, J.D. Brunzell, J.J.P. Kastelein and M.R. Hayden. J. Biol. Chem. 1992;267(3):1918-1923
19. Lipoproteine Lipase. Caput Selectum. J.J.P. Kastelein, T. Bruin, J.W. ten Cate. Ned. Tijdschr. Geneesk. 1992;15:727-730
20. High?Density Lipoproteine. Caput Selectum. J.J.P. Kastelein, R.P.G. Peters en J.W. ten Cate. Ned. Tijdschr. Geneeskd. 1992;136:723-726
21. De behandeling van Familiaire Hypercholesterolemie. Caput Selectum. P.J. Lansberg, J.J.P. Kastelein, J.C. Defesche en J.W. ten Cate. Ned. Tijdschr. Geneeskd. 1992;136:734-738
22. Familial high-density lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent. J.J.P. Kastelein, P.H. Pritchard, D.W. Erkelens, J.J. Albers, J.J. Frohlich. J. Int. Med. 1992;231:413-419
23. Postmenopausale oestrogeen substitutie en het risico voor atherosclerotische hart- en vaatziekten. Caput Selectum. Commentaar. E. Dekker, H.R. Büller and J.J.P. Kastelein. Ned. Tijdschr. Geneeskd. 1992;25:1197-1200.
24. A missense mutation (Asp250?Asn) in exon 6 of the human lipoprotein lipase gene causes hyperchylomicronemia in patients of different ancestries. Y. Ma, B.I. Wilson, S. Bijvoet, H.E. Henderson, E. Cramb, G. Roederer, M.R. McMurthy, P. Julien, H. Bakker, J.J.P. Kastelein, J.D. Brunzell, M.R. Hayden. Genomics. 1992;13:649-653.
25. Absence of mutations in the promoter region of the low density lipoprotein receptor gene in a large number of Familial Hypercholesterolemia patients as revealed by denaturing gradient gel electrophoresis. B. Top, A.G. Uiterlinden, A. v.d. Zee, J.J.P. Kastelein, J.A. Gevers Leuven, L.M. Havekes and R.R. Frants. Hum. Genet. 1992;89:561-565.
26. The familial hyperchylomicronaemia syndrome. S.M. Bijvoet, T. Bruin, J.J.P. Kastelein. Neth. J. Med. 1992;42:36-44.
27. Molecular Geography of Inherited Disorders of Lipoprotein Metabolism: Lipoprotein Lipase Deficiency and Familial Hypercholesterolemia. Hayden M.R., De Braekeleer M., Henderson H.E., and Kastelein J.J.P. Chapter in: Genetic Factors in Atherosclerosis-Candidate Genes and Processes. Eds. A.J. Lusis, J.I. Rotter and R.S. Sparkes. Monogr. Hum. Genet. Basel, Karger 1992;14:350-362.
28. A missense mutation (Pro157 ® Arg) in lipoprotein lipase (LPLnijmegen) resulting in loss of catalytic activity. T. Bruin, J.J.P. Kastelein, D.E. van Diermen, Y. Ma, H.E. Henderson, P.M.J. Stuyt, A.F.H. Stalenhoef, A. Sturk, J.D. Brunzell, M.R. Hayden. Eur. J. Biochem. 1992;208:267-272.
29. Detection of the Pro664 ® Leu mutation in the low-density lipoprotein-receptor gene and its relation to lipoprotein(a) levels in patients with familial hypercholesterolemia of Dutch ancestry from the Netherlands and Canada. J.C. Defesche, M.A. van de Ree, J.J.P. Kastelein, D.E. van Diermen, N.W.E. Janssens, J.J. van Doormaal and M.R. Hayden. Clin. Genet. 1992;42:273-280.
30. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (a multicenter comparative study). The European Study group. Am. J. Cardiol. 1992;70:1281-1286.
1993
31. Analysis of the Afrikaner mutation in exon 9 of the low-density lipoprotein receptor gene in a large Dutch kindred suffering from Familial Hypercholesterolemia. J.C. Defesche, P.J. Lansberg, P.W. Reymer, R.J. Lamping, J.J.P. Kastelein. Neth. J. Med. 1993; 42: 53-60.
32. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Y.Y. van der Hoek. M.E. Wittekoek, U. Beisiegel, J.J.P. Kastelein and M.L. Koschinsky. Hum. Mol. Genet., 1993; 2(4): 361-366.
33. Comparison of the efficacy, safety and tolerability of Simvastatin and Pravastatin for Hypercholesterolemia. The Simvastatin Pravastatin Study Group. Am. J. Cardiol. 1993; 71: 1408-1414.
34. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study. A.F.H. Stalenhoef, P.J. Lansberg, A.A. Kroon, B. Kortmann, A.F.J. de Haan, P.M.J. Stuyt and J.J.P. Kastelein. J. Intern. Med. 1993; 234; 77-82.
35. The identification of familial hypercholesterolemia in The Netherlands. J.J.P. Kastelein. Can. J. Cardiol. 1993; 9(suppl. d): 100D-101D.
36. Recurrent pancreatitis and chylomicronemia in an extended Dutch kindred is caused by a Gly154®Ser substitution in lipoprotein lipase. T. Bruin, S. Tuzgöl, D.E. van Diermen, N. Hoogerbrugge-v.d. Linden, J.D. Brunzell, M.R. Hayden, J.J.P. Kastelein. J. Lipid Res. 1993; 34: 2109-2119.
37. Structure-function relationships of lipoprotein lipase: mutation analysis and mutagenesis of the loop region. H.E. Henderson, Y. Ma, M-S. Liu, I. Clark-Lewis, D.L. Maeder, J.J.P. Kastelein, J.D. Brunzell, M.R. Hayden. J. Lipid Res. 1993; 34: 1593-1602.
38. South African founder mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia in the Dutch population. J.C. Defesche, D.E. van Diermen, P.J. Lansberg, R.J. Lamping, P.W.A. Reymer, M.R. Hayden, J.J.P. Kastelein. Hum. Genet. 1993; 92: 567-570.
39. Familial Defective Apolipoprotein B100 is clinically indistinguishable from Familial Hypercholesterolemia. J.C. Defesche, K.L. Pricker, M.R. Hayden, A.E. v.d. Ende, J.J.P. Kastelein. Arch. Int. Med. 1993; 153: 2349-2356.
1994
40. Phenotypic variation of mutations in the human lipoprotein lipase gene. M.R. Hayden, J.J.P. Kastelein. H. Funke, J.D. Brunzell, Y. Ma. Biochemical Society Trans. 1994; 21: 506-509.
41. Recurrent missense mutations at the first and second base of Codon Arg243 in human lipoprotein lipase in patients of different ancestries. Y. Ma, M.S. Liu, D. Chitayat, T. Bruin, U. Beisiegel, P. Benlian, L. Foubert, J.L. de Gennes, H. Funke, I. Forsythe, S. Blaichman, M. Papanikolaou, D.W. Erkelens, J.J.P. Kastelein, J.D. Brunzell, M.R. Hayden. Human Mutation. 1994; 3: 52-58.
42. Atherosclerose mede veroorzaakt door lokale vaatontsteking. S.J.H. van Deventer, J.J.P. Kastelein en J.W. ten Cate. Ned. Tijdschr. Geneeskd. 1994; 138: 443-448.
43. A compound heterozygote for lipoprotein lipase-deficiency: Val69®Leu and Gly188®Glu: correlation between in vitro LPL activity and clinical expression. T. Bruin, S. Tuzgol, W.J. Mulder, A.E. van den Ende, H. Jansen, M.R. Hayden and J.J.P. Kastelein. J. Lipid Res. 1994; 35: 438-445.
44. Homozygosity for a mutation in the lipoprotein lipase gene (Gly139®Ser) causes chylomicronemia in a boy of Spanish descent. S.M. Bijvoet, T. Bruin, S. Tuzgöl, H.D. Bakker, M.R. Hayden, J.J.P. Kastelein. Hum. Genet. 1994; 93: 339-343.
45. Screening for Familial Defective apolipoprotein B-100 with improved U937 monocyte proliferation assay. A.J.C.M. v.d. Broek, L. Hollaar, H.I.M.B. Schaefer, A. v.d. Laarse, H. Schuster, J.C. Defesche, J.J.P. Kastelein, F.M. van 't Hooft. Clin. Chim. 1994; 40(3): 395-399.
46. Decreased resistance against in vitro oxidation of low density lipoproteins from patients with familial defective apolipoprotein B100. A.F.H. Stalenhoef, J.C. Defesche, H.A. Kleinveld, P.N.M. Demacker, J.J.P. Kastelein. Arteriosclerosis and Thrombosis, 1994; 14: 489-493.
47. The C-terminus of lipoprotein lipase is essential for biological function but contains no domain for glycosylphosphatidylinositol anchoring. T. Bruin, N.B. Groot, J. Jansen, J.J.P. Kastelein. Eur. J. Biochem. 1994; 221: 1019-1025.
48. Analysis of structure-function relationships in human apolipoprotein(a). Y.Y. van der Hoek, J.J.P. Kastelein, M.L. Koschinsky. Can. J. Physiol. Pharmacol. 1994; 72: 304-310.
49. Apolipoprotein CIIPadova (Tyr37®Stop) underlying chylomicronemia in an Italian kindred from Sicily. S. Tuzgöl, S.M. Bijvoet, T. Bruin, J.J.P. Kastelein, M.R. Hayden. J. Med. Genet., 1994; 31: 622-626.
50. Gemfibrozil treatment of the high triglyceride-low high density lipoprotein cholesterol trait in men with established atherosclerosis. H.C. Knipscheer, M.T. Nurmohamed, A. van den Nede, B. Plaat, H.J.W. Pruijs, W.J. Mulder, J.J.P. Kastelein. J. Intern. Med. 1994, 236: 377-384.
51. Binding of recombinant apolipoprotein(a) to extracellular matrix proteins. Y.Y. van der Hoek, W. Sangrar, G.P. Côté, J.J.P. Kastelein, M.L. Koschinsky. Arteriosclerosis and Thrombosis, 1994; 14(11): 1792-1798.
52. Familial hypercholesterolemia in Dutch children: past, present and future. H.D. Bakker, L.M.J. Trum, J.C. Defesche, J.J.P. Kastelein. Int. Pediatrics, 1994; 9(3): 157-164.
53. The effect of Fiberform, a low phytate wheat fiber, on plasma lipids and blood pressure in women with Familial Hypercholesterolemia. H.C. Knipscheer, P.J. Lansberg, J.J.P. Kastelein, M. Nurmohamed, M.H. Prins, A.E. van der Ende, J.W. ten Cate. J. Int. Med. 1994; 236: 477-478.
54. The molecular and biochemical diagnosis and the therapy of familial hypercholesterolemia in childhood. H.D. Bakker, A. Wiegman, L. Feuth, J.C. Defesche, J.J.P. Kastelein. In: Current trends on the prevention of atherosclerosis in childhood. Proceedings of the International Congress on Prevention of Atherosclerosis in childhood. October 1994 Budapest, Hungary. Ed. Dr. Tamás Szamosi.
55. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2(Lys146®Gln) allele carriers. P. de Knijff, A.M.J.M. van den Maagdenberg, D.I. Boomsma, A.F.H. Stalenhoef, A.H.M. Smelt, J.J.P. Kastelein, A.D. Marais, R.R. Frants, L.M. Havekes. J. Clin. Invest. 1994; 94: 1252-1262.
1995
56. Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing. P. Lombardi, E.J.G. Sijbrands, K. van de Giessen, A.H.M. Smelt, J.J.P. Kastelein, R.R. Frants, L.M. Havekes. J. Lipid Res. 1995; 36: 860-867.
57. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. P.W.A. Reymer, E. Gagné, B.E. Groenemeyer, H. Zhang, I.J. Forsyth, H. Jansen, J.C. Seidell, D. Kromhout, K.E. Lie, J.J.P. Kastelein, M.R. Hayden. Nature Genetics, 1995; 10: 28-34.
58. A common variant in the gene for lipoprotein lipase (Asp9®Asn). Functional implications and prevalence in normal and hyperlipidaemic subjects. F. Mailly, Y. Tugrul, P.W.A. Reymer, T. Bruin, M. Seed, B.E. Groenemeyer, A. Asplund-Carlson, D. Vallance, A.F. Winder, G.J. Miller, J.J.P. Kastelein, A. Hamsten, G. Olivecrona, S.E. Humphries, Ph.J. Talmud. Arteriosclerosis and Thrombosis, 1995; 15: 468-478.
59. Apolipoprotein-E genotyping on agarose gels. P.W.A. Reymer, B.E. Groenemeyer, R. v.d. Burg, J.J.P. Kastelein. Clin. Chem. 1995; 41: 1046-1047.
60. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. P.W.A. Reymer, B.E. Groenemeyer, E. Gagné, Li Miao, E.E.G. Appelman, J.C. Seidel, D. Kromhout, S.M. Bijvoet, K. v.d. Oever, T. Bruin, M.R. Hayden, J.J.P. Kastelein. Hum Mol Genet 1995; 4: 1543-1549.
61. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. M.J.M. Diekman, P.J. Lansberg, J.J.P. Kastelein and W.M. Wiersinga. Arch Intern Med 1995; 155: 1490-1495.
62. Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. P.J. Lansberg, Y.B. Mitchel, D. Shapiro, J.J.P. Kastelein, R. Altman, G. Jerums, K. Bolzano, S. Giannini, J. Davignon, P. DeWailly, R. Darioli, M. Mancini, R. Scott, M.R. Hayden. Atherosclerosis 1995; 116: 153-162.
63. Comparison of Gemfibrozil versus Simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, loww-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. S.J.H. Bredie, T.W.A. de Bruin, P.N.M. Demacker, J.J.P. Kastelein, A.F.H. Stalenhoef. Am J Cardiol 1995; 75: 348-353.
64. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia. L. Ose, R. Scott and the Simvastatin-Fluvastatin Study Group. Clin Drug Invest 1995; 10: 127-138.
65. Patients with ApoE3 deficiency (E2/2, E3/2 and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291®Ser mutation in the human LPL gene. H. Zhang, P.W.A. Reymer, M.S. Liu, I.J. Forsythe, B.E. Groenemeyer, J. Frohlich, J.D. Brunzell, J.J.P. Kastelein, M.R. Hayden and Y. Ma. Arteriosclerosis and Thrombosis 1995; 15: 1695-1703..
66. Mutations in the gene for lipoprotein lipase: a cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia. S.N. Pimstone, E. Gagné, C. Gagné, P.J. Lupien, D. Gaudet, R.R. Williams, M. Kotze, P.W.A. Reymer, J.C. Defesche, J.J.P. Kastelein, S. Moorjani, M.R. Hayden. Arteriosclerosis & Thrombosis 1995; 15: 1704 - 1712.
67. A unique genetic and biochemical presentation of Fish-eye Disease. J.A. Kuivenhoven, E.J.G.M. van Voorst tot Voorst, H. Wiebusch, S.M. Marcovina, H. Funke, G. Assmann, P.H. Pritchard, J.J.P. Kastelein. J Clin Invest 1995; 96: 2783-2791.
1996
68. The lipoprotein lipase (Asn291®Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia. M.J.V. Hoffer, S.J.H. Bredie, D.I. Boomsma, P.W.A. Reymer, J.J.P. Kastelein, P. de Knijff, P.N.M. Demacker, A.F.H. Stalenhoef, L.M. Havekes, R.R. Frants. Atherosclerosis 1996; 119: 159-167.
69. Two novel molecular defects in the LCAT gene are associated with Fish-eye disease. J.A. Kuivenhoven, A.F.H. Stalenhoef, J.S. Hill, P.N.M. Demacker, A. Errami, J.J.P. Kastelein, P.H. Pritchard. Arterioscler Thromb Vasc Biol. 1996; 16: 294-303.
70. Alterations in plasma lipoproteins and apoproteins before the age of 40 in heterozygotes for LPL deficiency. S.M. Bijvoet, S.E. Gagné, S. Moorjani, C. Gagné, H.E. Henderson, J.C. Fruchart, J. Dallongeville, P. Alaupovic, M. Prins, J.J.P. Kastelein, M.R. Hayden. J Lipid Res 1996; 37: 640-650.
71. Short-term efficacy and safety of Pravastatin in 72 children with familial hypercholesterolemia. H.C. Knipscheer, C.C.A. Boelen, J.J.P. Kastelein, D.E. van Diermen, B.E. Groenemeyer, A.E. van den Ende, H.D. Bakker. Paediatric Res 1996; 39: 867-871.
72. MED PED: an integrated strategy for preventing early deaths. Williams RR, Hamilton-Craig I, Kostner GM, Hegele RA, Hayden MR, Pimstone SN, Faergeman I, Schuster H, Steinhage-Thiessen E, Beisiegel U, Keller C, Czeizel A, Leitersdorf E, Kastelein JJP, Defesche JC, Ose L, Leren T, Seftel HC, Raal FJ, Marais AD, Eriksson M, Keller U, Miserez A, Jeck T, Betteridge DJ, Humphries SE, Day INM, Kwiterovich PO, Lees RS, Stein E, Illingworth R, Kane J and Bouyjenkov V.1996. WHO/Ipsen Foundation/ Springer Verlag Berling. pp. 35-45
73. Compound heterozygosity for a known (D250N) and a novel (E410K) missense mutation in the C-terminal domain of lipoprotein lipase causes familial chylomicronemia. H. Wiebusch, H. Funke, T. Bruin, H. Bucher, A. von Eckardstein, J.J.P. Kastelein and G. Assmann. Hum Mutation 1996; 8: 381-383.
74. Hormone replacement therapy: a useful tool in the prevention of coronary artery disease in postmenopausal women? The working group on women and cardiovascular disease of the Netherlands Heart Foundation. Eur Heart J 1996; 17: 658-666.
75. An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease). J.A. Kuivenhoven, H. Wiebusch, P.H. Pritchard, H. Funke, R. Benne, G. Assmann, J.J.P. Kastelein. J Clin Invest 1996; 98: 358-364.
76. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidemia. H.C. Knipscheer, J.C. de Valois, A. van den Ende, J.W. ten Cate, J.J.P. Kastelein. Atherosclerosis 1996; 124 (suppl.) S75-S81.
77. Origin and migration of an Afrikaner founder mutation FHAfrikaner-2 (V408M) causing familial hypercholesterolemia. J.C. Defesche, D.E. van Diermen, M.R. Hayden, J.J.P. Kastelein. Gene Geography 1996; 10: 1-10.
78. Lipoprotein(a). A. van den Ende, Y.Y. van der Hoek, J.J.P. Kastelein, M.L. Koschinsky, C. Labeur, M. Rosseneu. Adv Clin Chem 1996; 32: 73-134.
79. Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250®Asn and Ser251®Cys) resulting in lipoprotein lipase (LPL) deficiency. S.M. Bijvoet, H. Wiebusch, Y. Ma, P.W.A. Reymer, T. Bruin, H.D. Bakker, H. Funke, G. Assmann, M.R. Hayden and J.J.P. Kastelein. Neth J Med 1996; 49: 189-195.
80. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. J.W. Jukema, A.J. van Boven, B.E. Groenemeijer, A.H. Zwinderman, J.H.C. Reiber, A.V.G. Bruschke, J.A. Henneman, G.P. Molhoek, T. Bruin, H. Jansen, E. Gagné, M.R. Hayden, J.J.P. Kastelein; Circulation 1996; 94: 1913-1918.
81. A common alteration in the LPL gene resulting in altered lipoprotein levels. S. Pimstone, E. Gagné, H. Zhang, P.W.A. Reymer, J.J.P. Kastelein, Y. Ma, M.R. Hayden. In: Pennington Center Nutrition Series. Volume 6: Nutrition, genetics and heart disease. G.A. Bray, D.H. Ryan, eds. pp: 258-275.
82. Identification of a double mutation in the low density lipoprotein receptor gene causing familial hypercholesterolemia. P. Lombardi, S.W.A. Kamerling, J.C. Defesche, J.J.P. Kastelein, L.M. Havekes. Clin Genet 1996; 50: 525-526.
83. Modulation of plasma fibrinogen levels by medication. M.P.M. de Maat, M. Kockx, J.J.P. Kastelein, C. Kluft. Fibrinolysis 1996; 10: suppl. 4: 7.
1997
84. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. E.S.G. Stroes, J.J.P. Kastelein, F. Cosentino, D.W. Erkelens, R. Wever, H.A. Koomans, T.F. Lüscher, T.J. Rabelink. J Clin Invest 1997; 99: 41-46.
85. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. M.P.M. de Maat, H.C. Knipscheer, J.J.P. Kastelein, C. Kluft. Thrombosis & Haemostasis 1997; 77: 75-79.
86. Mutation of tryptophan residues in lipoprotein lipase. Effects on stability, immunoreactivity and catalytic properties. A. Lookene, N.B. Groot, J.J.P. Kastelein, G. Olivecrona and T. Bruin. J Biol Chem 1997; 272: 766-772.
87. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J.A. Kuivenhoven, H. Pritchard, J. Frohlich, G. Assmann, J.J.P. Kastelein. J Lipid Res 1997; 38: 191-205
88. The Ser447-Stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. J.A. Kuivenhoven, B.E. Groenemeijer, J.M.A. Boer, P.W.A. Reymer, R. Berghuis, T. Bruin, H. Jansen, J.C. Seidell, J.J.P. Kastelein. Arterioscler Thromb Vasc Biol 1997; 17: 595-599
89. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. J.A. Kuivenhoven, P. de Knijff, J.M.A. Boer, H.A. Smalheer, G.J. Botma, J. Seidell, J.J.P. Kastelein and P.H. Pritchard. Arterioscler Thromb Vasc Biol 1997; 17: 560-568
90. Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries. P.S. Hansen, J.J.P. Kastelein, L.U. Gerdes, L. Fraza, C. Gerdes, F. Tato, H.K. Jensen, L.G. Jensen, I.C. Klausen, O. Faergeman, H. Schuster. Arterioscler Thromb Vasc Biol 1997; 17: 741-747.
91. Magnesium-pyridoxal-5-phosphate glutamate "A vitamin B6 derivative", does not affect lipoprotein levels in patients with familial hypercholesterolemia. H.C. Knipscheer, I. Kindt, A.E. van den Ende, M.T. Nurmohamed, H. Smalbraak, W.J. Mulder, J.J.P. Kastelein. Eur J Clin Pharmacol 1997; 51: 499-503.
92. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia. S.N. Pimstone, J.C. Defesche, S.M. Clee, H.D. Bakker, M.R. Hayden, J.J.P. Kastelein. Arterioscler Thromb Vasc Biol 1997; 17: 826-832.
93. Short report on DNA marker at candidate locus. A novel V415A mutation in exon 9 of the low density lipoprotein receptor gene causing familial hypercholesterolemia. P. Lombardi, J.C. Defesche, S.W.A. Kamerling, J.J.P. Kastelein, L.M. Havekes. Clin Genet 1997; 51: 286-287.
94. Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective apoB. Y.Y. van der Hoek, A. Lingenhel, H.G. Kraft, J.C. Defesche, J.J.P. Kastelein, G. Utermann. J Clin Invest 1997; 99: 2269-2273.
95. Genetic variant showing a positive interaction with ?-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in CAD patients. The Ser447Stop substitution in the lipoprotein lipase gene. B.E. Groenemeijer, M.D. Hallman, P.W.A. Reymer, E. Gagné, J.A. Kuivenhoven, T. Bruin, H. Jansen, K.I. Lie, A.V.G. Bruschke, E. Boerwinkle, M.R. Hayden and J.J.P. Kastelein. Circulation 1997; 95:2628-2635.
96. The identification and significance of a Thr->Pro polymorphism in Kringle IV type 8 of apolipoprotein (a). J. Prins, F.R. Leus, Y.Y. van der Hoek, J.J.P. Kastelein, B.N. Bouma, H.J.M. van Rijn. Trombosis & Haemostasis 1997; 77: 949-954.
97. A single Ser259Arg mutation in the gene for lipoprotein lipase causes chylomicronemia in Moroccans of Berber ancestry. L. Foubert, T. Bruin, J.L. de Gennes, E. Ehrenborg, J. Furioli, J.J.P. Kastelein, P. Benlian, M.R. Hayden. Human Mutation. 1997; 10: 179-185.
98. Lipoprotein(a) is not present in the plasma of patients with some peroxisomal disorders. Y.Y. van der Hoek, R.J.A. Wanders, A.E. van den Ende, H.G. Kraft, J.J.P. Kastelein, M.L. Koschinsky. J Lipid Res 1997; 8: 1612-1619.
99. Effects of gemfibrozil or simvastatin on apolipoprotein-B containing lipoproteins, apolipoproteins-CIII and lipoprotein(a) in familial combined hyperlipidemia. S.J.H. Bredie, H.E. Westerveld, H.C. Knipscheer, T.W.A. de Bruin, J.J.P. Kastelein and A.F.H. Stalenhoef. Neth. J. Med. 1997; 49: 59-67.
100. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue type plasminogen activator, plasminogen activator inhibitor 1 and fibrinogen in hyperlipidaemic patients. M. Kockx, M.M.P. de Maat, H.C. Knipscheer, J.J.P. Kastelein, C. Kluft, H.M.G. Princen, T. Kooistra. Trombosis & Haemostasis 1997; 78: 1167-1172.
101. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. L.A.J. Kluijtmans, J.J.P. Kastelein, J. Lindemans, G.H.J. Boers, S.G. Heil, A.V.G. Bruschke, W.J. Jukema, L.P.W.J. van den Heuvel, F.J.M. Trijbels, G.J.M. Boerma, F.W.A. Verheugt, F. Willems, H.J. Blom. Circulation 1997; 96: 2573-2577.
102. Short report on DNA marker at candidate locus. A novel mutation M-21V in exon 1 of the low density lipoprotein receptor gene causing familial hypercholesterolemia. P. Lombardi, J.C. Defesche, S.W.A. Kamerling, J.J.P. Kastelein, L.M. Havekes. Clin Genet 1997; 51: 430-431.
103. Ethnic variation and in-vivo effects of the -93?Promoter variant in the lipoprotein lipase gene. E. Ehrenborg, S.M. Clee, S.N. Pimstone, P.W.A. Reymer, P. Benlian, C.F. Hoogendijk, H.J. Davis, N. Bissada, L. Miao, S.E. Gagné, J. Greenberg, H. Henderson, J.M. Ordovas, E.J. Schaefer. J.J.P. Kastelein, M.J. Kotze and M.R. Hayden. Arterioscler Thromb Vasc Biol.1997; 17: 2672-2679.
104. A common C-to-T substitution at position -480 of the hepatic lipase promotor associated with a lowered lipase activity in coronary artery disease patients. H. Jansen, A.J.M. Verhoeven, L. Weeks, J.J.P. Kastelein, D.J.J. Halley, A. Van den Ouweland, J.W. Jukema, J.C. Seidell, J.C. Birkenhäger. Arterioscler Thromb Vasc Biol 1997; 17: 2837 - 2843.
105. Is opsporing van familiaire hypercholesterolemie geïndiceerd bij kinderen? H.D. Bakker, A. Wiegman, J.C. Defesche, J.J.P. Kastelein. Ned Tijdschr Geneeskd 1997; 141: 2548-2551.
106. Risk of progression of coronary atherosclerosis is influenced by a common functional variant in the human stromelysin-1 gene promoter. M.P.M. de Maat, J.W. Jukema, S. Ye, A.H. Zwinderman, M. Beekman, J.J.P. Kastelein, A.J. van Boven, A.V.G. Bruschke, S.E. Humphries, C. Kluft, A.M. Henney. Conceptuur, 1997; 14: 37-38.
1998
107. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. J.A. Kuivenhoven, J.W. Jukema, A.H. Zwinderman, P. de Knijff, R. McPherson, A.V.G. Bruschke, K.I. Lie, J.J.P. Kastelein, also on behalf of the REGRESS study group. New Eng J Med 1998; 338: 86-93.
108. The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. J.J.P. Kastelein, B.E. Groenemeijer, M.D. Hallman, H. Henderson, P.W.A. Reymer, S.E. Gagné, H. Jansen, J.C. Seidell, D. Kromhout, J.W. Jukema, A.V.G. Bruschke, E. Boerwinkle, M.R. Hayden, also on behalf of the Regress Study Group. Clinical Genetics1998; 53: 27-33.
109. -445G/A polymorphism of the?-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Proposed role for an acute-phase reaction pattern of fibrinogen. M.P.M. de Maat, J.J.P. Kastelein, J.W. Jukema, A.H. Zwinderman, H. Jansen, B.E. Groenemeijer, A.V.G. Bruschke, C. Kluft, on behalf of the REGRESS group. Arterioscler Thromb Vasc Biol. 1998; 18: 265-271.
110. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolaemia. M.C. Verhaar, R.M.F. Wever, J.J.P. Kastelein, T. van Dam, H.A. Koomans, T.J. Rabelink. Circulation 1998; 97: 237-241.
111. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with Familial Hypercholesterolemia. M.E. Wittekoek, S.N. Pimstone, P.W.A. Reymer, L. Feuth, G.J. Botma, J.C. Defesche, M. Prins, M.R. Hayden, J.J.P. Kastelein. Circulation 1998; 97: 729-735.
112. Optimale reductie van cardiovasculair risico: wie verdient behandeling met HMG-CoA reductaseremmers? M.J. van Dam, J.J.P. Kastelein. Cardiologie 1998; 5: 143-145. Editorial.
113. Gender-related association between the -93T®G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. M.J.V. Hoffer, S.J.H. Bredie, H. Snieder, P.W.A. Reymer, P.N.M. Demacker, L.M. Havekes, D.I. Boomsma, A.F.H. Stalenhoef, R.R. Frants, J.J.P. Kastelein. Atherosclerosis 1998; 138: 91-99.
114. Lipid-free apolipoprotein (apo) A-I is converted into alpha-migrating high density lipoproteins by lipoprotein-depleted plasma of normolipidemic donors and apo A-I-deficient patients but not of Tangier disease patients. A. von Eckardstein, Y. Huang, J.J.P. Kastelein, J. Geisel, J.T. Real, J.A. Kuivenhoven, R. Miccoli, G. Noseda, G. Assmann. Atherosclerosis 1998; 138: 25-34.
115. Ile225Thr loop mutation in the lipoprotein lipase (LPL) gene is a de novo event. H.E. Henderson, S.M. Bijvoet, M.A.M.M. Mannens, T. Bruin, D.W. Erkelens, M.R. Hayden, J.J.P. Kastelein. Am J Med Gen 1998; 78: 313-316.
116. The functional and clinical significance of the Met®Thr subsitution in kringle IV type 10 of apolipoprotein(a). J. Prins, Y.Y. van der Hoek, T.H. Biesheuvel, F.R. Leus, H.J.M. van Rijn, J.J.P. Kastelein. Thrombosis Research 1998; 90: 125-130.
117. Efficacy and six-month safety of simvastatin 80 mg/day: Results from the Worldwide Simvastatin Expanded Dose Program (WSEDP). L. Ose. J.J.P. Kastelein, R. Scott, E.A. Stein, S. Campodonico, I.D. Escobar, A.C. Tate, L. Corsetti, A. Shahane, Y.B. Mitchel, M. Mercuri for the WSEDP Research Group. Nutr. Metab. Cardiovasc. Dis. 1998; 8: 135-143.
118. Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I. A. von Eckardstein, A. Chirazi, S. Schuler-Lüttmann, M. Walter, J.J.P. Kastelein, J. Geisel, J.T. Real, R. Miccoli, G. Noseda, G. Höbbel, G. Assmann. J Lipid Res 1998; 39: 987-998.
119. Increased oxidizability of low density lipoproteins in hypothyroidism. Th. Diekman, P.N.M. Demacker, J.J.P. Kastelein, A.F.H. Stalenhoef, W.M. Wiersinga. J Clin Endocrinol Metab. 1998; 83: 1752-1755.
120. Behandeling en preventie van coronaire hartziekten door verlaging van de serumcholesterolconcentratie; derde consensus 'Cholesterol'. M.L. Simoons en A.F. Casparie, namens de voorbereidingswerkgroep 3e cholesterol consensus. Ned Tijdschr Geneeskd 1998; 38: 2096-2101.
121. Molecular epidemiology of familial hypercholesterolaemia. J.C. Defesche, J.J.P. Kastelein. Lancet 1998; 352: 1643-1644.
122. Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. S. Rust, M. Walter, H. Funke, A. von Eckardstein, P. Cullen, H.Y. Kroes, R. Hordijk, J. Geisel, J.J.P. Kastelein, H.O.F. Molhuizen, M. Schreiner, A. Mischke, H.W. Hahmann, G. Assmann. Nature Genetics 1998; 20: 96-98.
123. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. B.J. Verhoeff, M.D. Trip, M.H. Prins, J.J.P. Kastelein, P.H. Reitsma. Atherosclerosis 1998; 141: 161-166.
124. Familial hypercholesterolemia: molecular genetics and clinical expression. J.C. Defesche, M.E. Wittekoek, J.J.P. Kastelein. Atherosclerosis XI B. Jacotot, D. Mathé, J.C. Fruchart, editors. 1998, 709-712.
125. Optimal reduction in cardiovascular risk: whom should we treat with HMG-CoA reductase inhibitors. J.J.P. Kastelein. Atherosclerosis XI B. Jacotot, D. Mathé, J.C. Fruchart, editors. 1998, 289-293.
126. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. R.F. Franco, M.A. Zago, M.D. Trip, H. ten Cate, A. van den Ende, M.P. Prins, J.J.P. Kastelein, P.H. Reitsma. Brit J Haematol 1998; 102: 1172-1175.
127. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. M. Farnier, and the Cerivastatin Study Group. Am J Cardiol 1998; 82: 47j-51j.
1999
128. Effect of the Stromelysin-1 Promotor on Efficacy of Pravastatin in Coronary Atherosclerosis and Restenosis. M.P.M. de Maat, J.W. Jukema, Shu Ye, A.H. Zwinderman, P.H. Moghadaam, M. Beekman, J.J.P. Kastelein, A.J. van Boven, A.V.G. Bruschke, S.E. Humphries, C. Kluft, A.M. Henney. Am J Cardiol 1999; 83: 852-856.
129. The future of best practice. J.J.P. Kastelein. Atherosclerosis 1999, 143 (Supp. 1) S17-S21.
130. Bringing about best practice in atherosclerosis. J.J.P. Kastelein. Atherosclerosis 1999, 143 (Supp. 1) S1.
131. Nitric oxide production is reduced in patients with chronic renal failure. R. Wever, P. Boer, M. Hijmering, E. Stroes, M. Verhaar, J.J.P. Kastelein, K. Versluis, F. Lagerwerf, H. van Rijn, H. Koomans, T. Rabelink. Arterioscler Thromb Vasc Biol 1999; 19: 1168-1172.
132. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. M.C. Verhaar, M.L.H. Honing, Th. van Dam, M. Zwart, H.A. Koomans, J.J.P. Kastelein, T.J. Rabelink. Cardiovasc. Res. 1999; 42: 752-760.
133. The 20210 G ® A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. R.F. Franco, M.D. Trip, H. ten Cate, A. van den Ende, M.H. Prins, J.J.P. Kastelein, P.H. Reitsma. British Journal of Haematology 1999; 104: 50-54.
134. Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. H.E. Henderson, J.J.P. Kastelein, A.H. Zwinderman, E. Gagne, W.J. Jukema, P.W.A. Reymer, B.E. Groenemeijer, K.I. Lie, A.V.G. Bruschke, M.R. Hayden, H. Jansen. J. Lipid Res. 1999; 40: 735-743.
135. Familial Hypercholesterolemia. Acceptor Splice Site (G®C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. L. Yu, E. Heere-Ress, B. Boucher, J.C. Defesche, J.J.P. Kastelein, M.A. Lavoie, J. Genest Jr. Atherosclerosis. 1999; 146: 125-131.
136. A common truncation variant of lipoprotein lipase (S447X) confers protection against coronary heart disease: The Framingham Offspring Study. S.E. Gagné, M.G. Larson, S.N. Pimstone, E.J. Schaefer, J.J.P. Kastelein, P.W.F. Wilson, J.M. Ordovas, M.R. Hayden. Clin Genet 1999; 55: 450-454.
137. Mutations in the ABC1 in Tangier disease and familial high-density lipoprotein deficiency. A. Brooks-Wilson, M. Marcil, S.M. Clee, L.H. Zhang, K. Roomp, M.J. van Dam, L. Yu, C. Brewer, J.A. Collins, H.O.F. Molhuizen, O. Loubser, B.F.F. Ouelette, K. Fitchter, K.J.D. Ashbourne-Excoffen, C.W. Sensen, S. Scherer, S. Mott, M. Denis, D. Martindale, J. Frohlich, K. Morgan, B. Koop, S.N. Pimstone, J.J.P. Kastelein, J. Genest Jr., M.R. Hayden. Nature Genetics 1999; 22: 336-345.
138. Opsporing van patienten met Familiaire Hypercholesterolemia in Nederland. M.A.W. Umans-Eckenhausen, J.C. Defesche, R.L.J.M. Scheerder, F. Cliné, J.J.P. Kastelein. Ned Tijdschr Geneeskd 1999; 143: 1157-1161.
139. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. M.C. Verhaar, R.M.F. Wever, J.J.P. Kastelein, D. van Loon, S. Milstien, H.A. Koomans, T.J. Rabelink. Circulation 1999; 100: 335-338.
140. Physical activity modulates the effect of a lipoprotein lipase mutation (D9N) on plasma lipids and lipoproteins. J.M.A. Boer, J.A. Kuivenhoven, E.J.M. Feskens, E.G. Schouten, L.M. Havekes, J.C. Seidell, J.J.P. Kastelein, D. Kromhout. Clin. Genetics. 1999; 56: 158-163.
141. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. M. Marcil, A. Brooks-Wilson, S.M. Clee, K. Roomp, L.-H. Zhang, L. Yu, J.A. Collins, M. van Dam, H.O.F. Molhuizen, O. Loubster, B.F.F. Ouellette, C.W. Sensen, K. Fichter, S. Mott, M. Denis, B. Boucher, S.N. Pimstone, J. Genest Jr, J.J.P. Kastelein. The Lancet 1999; 354: 1341-1346.
142. Activation of the contact system of coagulation does not contribute to the hemostatic imbalance in hypertriglyceridemia. M.C. Minnema, M.E. Wittekoek, N. Schoonenboom, J.J.P. Kastelein, C.E. Hack, H. ten Cate. Arterioscler Thromb Vasc Biol 1999; 19: 2548-2553.
143. Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. M.E. Wittekoek, E. de Groot, M.H. Prins, M.D. Trip, H.R. Büller, J.J.P. Kastelein. Atherosclerosis. 1999; 146: 271-279.
144. Molecular basis of genetic dyslipidemia. H.O.F. Molhuizen, J.C. Defesche, M.D. Trip, J.J.P. Kastelein. CVR&R 1999; 20: 607 - 619.
145. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. M.E. Wittekoek, E. Moll, S.N. Pimstone, M.D. Trip, P.J. Lansberg, J.C. Defesche, J.J. van Doormaal, M.R. Hayden and J.J.P. Kastelein. Arterioscler Thromb Vasc Biol 1999; 19: 2708-2713.
146. Farmacogenomie en atherosclerose. Genetische variatie in het lipidenmetabolisme. H.O.F. Molhuizen, J.J.P. Kastelein. In: Ziekten maken en breken. Over farmacogenomie. Eds. J.J.E. van Everdingen, A.F. Cohen, G. Feenstra. pp. 55-61.
147. Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. J.J.P. Kastelein, J.M. Ordovas, M.E. Wittekoek, S.N. Pimstone, P.W.F. Wilson, S.E. Gagné, M.G. Larson, E.J. Schaefer, J.M.A. Boer, Ch. Gerdes, M.R. Hayden. Clin genet. 1999; 56: 297-305.
148. Stoornissen in de vetstofwisseling. Vele oorzaken, fatale gevolgen. J.J.P. Kastelein. Pharm Weekblad 1999; 134; 1659-1664.
149. Analysis of lipoprotein lipase haplotypes reveals association not apparent from analysis of the constituent loci. D.M. Hallman, B.E. Groenemeijer, J.W. Jukema, E. Boerwinkle, J.J.P. Kastelein. Ann Hum Genet 1999; 63: 499-510.
2000
150. Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease. J. Heikens, M.C. Ubbink, H.P.J. van der Pal, P.J.M. Bakker, E. Fliers, T.J. Smilde, J.J.P. Kastelein, M.D. Trip. Cancer 2000; 88: 2116-2121.
151. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. M.R. Hayden, S.M. Clee, A. Brooks-Wilson, J. Genest Jr, A. Attie and J.J.P. Kastelein. Curr Opin Lipidol 2000; 11: 117-122.
152. Molecular genetic testing for Familial Hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands. M.P. Lombardi, E.J.W. Redeker, J.C. Defesche, S.W.A. Kamerling, M.M.A.M. Mannens, L.M. Havekes, J.J.P. Kastelein. Clin Genet 2000; 57: 116-124.
153. Additional risk factors influence excess mortality in heterozygous familial hypercholaemia. E.J.G. Sijbrands, R.G.J. Westendorp, M.P. Lombardi, L.M. Havekes, R.R. Frants, J.J.P. Kastelein, A.H.M. Smelt. Atherosclerosis 2000; 149: 421-425.
154. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. F.R. Leus, M.E. Wittekoek, J. Prins, J.J.P. Kastelein, H.A.M. Voorbij. Atherosclerosis 2000; 149: 371-377.
155. Mutations in ABC1 in Tangier disease and familial high density lipoprotein deficiency. M. Marcil, A. Brooks-Wilson, J.J.P. Kastelein, M.R. Hayden, J. Genest Jr. Médecine Sciences 2000; 3: 421-430.
156. Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. G. Liu, K.J.D. Ashbourne-Excoffon, J.E. Wilson, B.M. McManus, Q.R. Rogers, L. Miao, J.J.P. Kastelein, M.E.S. Lewis, M.R. Hayden. Human Gene Therapy 2000; 11: 21-32.
157. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. S.M. Clee, N. Bissada, F. Miao, L, Miao, A.D. Marais, H.E. Henderson, P. Steures, J. McManus, B. McManus, R.C. LeBoeuf, J.J.P. Kastelein, M.R. Hayden. J Lipid Res 2000; 41: 521-531.
158. Additional efficacy of milligram-equivalent doses of atorvastatin over simvastatin. M. van Dam, D.C.G. Basart, Ch. Janus, R. Zwertbroek, H.A.M. Spierenburg, H.A. Werner, A.C. Bredero, P.J. Lansberg, C.J. Jonker, M.D. Trip, M.H. Prins, J.J.P. Kastelein. Clin Drug Invest 2000; 19: 327-334.
159. Additional efficacy of milligram-equivalent doses of atorvastatin over simvastatin. M. van Dam, D.C.G. Basart, Ch. Janus, R. Zwertbroek, H.A.M. Spierenburg, H.A. Werner, A.C. Bredero, P.J. Lansberg, C.J. Jonker, M.D. Trip, M.H. Prins, J.J.P. Kastelein. Cardiologie 2000; 7: 173-178.
160. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolemia. T.J. Smilde, F.W. van den Berkmortel, H. Wollersheim, H. van Langen, J.J.P. Kastelein, A.F.H. Stalenhoef. Eur J Clin Invest 2000; 30: 473-480.
161. The ILIB Lipid Handbook for Clinical Practice. Blood lipids and coronary heart disease. Second Edition. Authors.: A.M. Gotto, G. Assmann, R. Carmena, J. Davignon, A. Fernandex-Cruz, J.C. Fruchart, J.J.P. Kastelein, R. Paoletti.
162. Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. L. Ose, M.H. Davidson, E.A. Stein, J.J.P. Kastelein, R.S. Scott, D.B. Hunninghake, S. Campodonico, W. Insull, I.D. Escobar, H.G. Schrott, M.E. Stepanavage, M. Wu, A.C. Tate, M.R. Melino, M. Mercuri, Y.B. Mitchel, for the world wide expanded dose simvastatin study group. Clin Cardiol 2000; 23: 39-46.
163. Tailored therapy to fit individual profiles; genetics and coronary arthery disease. J.W. Jukema, J.J.P. Kastelein. In: Atherosclerosis V. The Fifth Saratoga International Conference. Eds.: F. Numano, M.A. Gimbrone Jr. Elseviers publishers, pp. 17-26.
164. Prevalentie van Familiaire Hypercholesterolemie onder volwassenen in vier huisartsenpraktijken hoger dan werd aangenomen. P.J. Lansberg, S. Tuzgöl, M.A. van de Ree, J.C. Defesche, J.J.P. Kastelein. Ned Tijdschr Geneeskd 2000; 144: 1437-1440.
165. Familiaire hypercholesterolemie: cardiovasculaire complicaties op jonge leeftijd te verwachten en te voorkomen. M.D. Trip, P.J. Lansberg, S. de Jongh, J.J.P. Kastelein. Ned Tijdschr Geneeskd 2000; 144: 1425-1428.
166. Comparison of effects of simvastatin versus atorvastatin on high density lipoprotein cholesterol and apolipoprotein A-I levels. J.J.P. Kastelein, J.L. Iscaacsohn, L. Ose, D.B. Hunninghake, J. Frohlich, M.H. Davidson, R. Habib, C.A. Dujovne, J.R. Crouse, M. Liu, M.R. Melino, L. O'Grady, M. Mercuri, Y.B. Mitchel, for the Simvastatin Atorvastatin HDL Study Group. Am J Cardiol 2000; 86: 221-223.
167. Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs. conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolemia. T.J. Smilde, M.D. Trip, H. Wollersheim, S. van Wissen, J.J.P. Kastelein, A.F.H. Stalenhoef. Clin Drug Invest 2000; 20: 67-79.
168. The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia. M.J.V. Hoffer, H. Snieder, S.J.H. Bredie, P.N.M. Demacker, J.J.P. Kastelein, R.R. Frants, A.F.H. Stalenhoef. Atherosclerosis 2000; 151: 443-450.
169. Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia. K.L. Khoo, J.C. Defesche, H. Tan, L. van de kerkhof, S.J. Heijnen-van Eijk, J.J.P. Kastelein, J.P. Deslypere. Clin Genet 2000; 58: 98-105.
170. Lipoprotein lipase activity is associated with the severity of angina pectoris. J.J.P. Kastelein, J.W. Jukema, A.H. Zwinderman, S. Clee, A.J. van Boven, H. Jansen, T.J. Rabelink, R.J.G. Peters, K.I. Lie, G. Liu, Y. Zhou, A.V.G. Bruschke, M.R. Hayden. Circulation 2000; 102: 1629-1633.
171. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. S.M. Clee, J.J.P. Kastelein, M.J. van Dam, M. Marcil, K. Roomp, K.Y. Zwarts, J.A. Collins, R. Roelants, N. Tamasawa, T. Stulc, T. Suda, R. Ceska, B. Boucher, C. Rondeau, C. DeSouich, A. Brooks-Wilson, H.O.F. Molhuizen, J. Frohlich, J. Genest, M.R. Hayden. J Clin Invest 2000; 106: 1263-1270.
172. Screening for Familial Hypercholesterolaemia.Effective, safe treatments and DNA testing make screening attractive. J.J.P. Kastelein. BMJ. 2000; 321: 1483-1484.
173. The effect of concentrated N-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. A.F.H. Stalenhoef, J. de Graaf, M.E. Wittekoek, S.J.H. Bredie, P.N.M. Demacker, J.J.P. Kastelein. Atherosclerosis, 2000; 153: 129-138.
174. Optimal treatment for patients with dyslipidaemia. M.D. Trip, J.J.P. Kastelein. Cardiologie 2000; 7: 466-470.
2001
175. Review of first 5 years of screening for familial hypercholesterolemia in The Netherlands. M.A.W. -Eckenhausen, J.C. Defesche, E.J.G. Sijbrands, R.L.J.M. Scheerder, J.J.P. Kastelein. The Lancet. 2001; 357: 165-168. Rewarded with the IFCC/EDMA Award
176. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. S.M. Clee, A.H. Zwinderman, J.C. Engert, K. Zwarts, H.O.F. Molhuizen, K. Roomp, , J.W. Jukema, M. van Wijland, M. van Dam, T. Hudson, A. Brooks-Wilson, J. Genest Jr., J.J.P. Kastelein, M.R. Hayden. Circulation 2001; 103: r13-r20.
177. Parental history of myocardial infarction: lipid traits, gene polymorphisms and lifestyle. J.M.A. Boer, E.J.M. Feskens, J.A. Kuivenhoven, E.G. Schouten, L.M. Havekes, J.J.P. Kastelein, J.C. Seidell, D. Kromhout. Atherosclerosis 2001; 155: 149-156.
178. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. T.J. Smilde, S. van Wissen, H. Wollersheim, M.D. Trip, J.J.P. Kastelein, A.F.H. Stalenhoef. The Lancet 2001; 357: 577-581.
179. Efficacy of concentrated n-3 fatty acids in hypertriglyceridaemia. A comparison with gemfibrozil. M. van Dam, A.F.H. Stalenhoef, J. Wittekoek, M.D. Trip, M.H. Prins, J.J.P. Kastelein. Clin Drug Invest 2001; 21: 175-181.
180. A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease. M.J. van Dam, H.J.A.M. Penn, F.R. den Hartog, H.A. Kragten, M.D. Trip, F.J.A. Buirma, J.J.P. Kastelein for the MUST study group. Clinical Therapeutics 2001; 23: 467-478.
181. Increased risk for ischemic events is related to combined RAS polymorphisms. P.P. van Geel, Y.M. Pinto, A.H. Zwinderman, R.H. Henning, A.J. van Boven, J.W. Jukema, A.V.G. Bruschke, J.J.P. Kastelein, W.H. van Gilst on behalf of the REGRESS study group. Heart 2001; 85: 458-462.
182. Preventie van coronaire hartziekten: de toekomst van de beste behandeling. J.J.P. Kastelein en A.F.H. Stalenhoef. Hartbulletin. 2001; 3: 60-63.
183. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. E.J.G. Sijbrands, R.G.J. Westendorp, J.C. Defesche, P.H.E.M. de Meijer, A.H.M. Smelt, J.J.P. Kastelein. BMJ 2001; 322: 1019-1023.
184. Familiaire Hypercholesterolemie. J.C. Defesche, J.J.P. Kastelein. Bijblijven 2001; 17: 24-32.
185. Efficacy and tolerability of fluvastatin in a titration dosage regimen in hyperlipidaemic patients. Results of a multicentre phase IV study. M. van Dam, J.J.P. Kastelein, on behalf of the Fluvastatin Collaboration Group. Clin Drug Invest 2001; 21: 477-484.
186. Wettelijk kader voor genetische screening in Nederland ontbreekt. M.A.W. Umans-Eckenhausen, J.J.P. Kastelein, R.L.J.M. Scheerder. TSG 2001; 5: 314-316.
187. Results from a family and DNA based active identification programme for Familial Hypercholesterolemia. A.H.A. ten Asbroek, P.J. Marang-van der Mheen, J.C. Defesche, J.J.P. Kastelein, L.J. Gunning-Schepers. J Epidemiol & Community Health 2001; 55: 500-502.
188. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. F.R. Leus, M. Zwart, J.J.P. Kastelein, H.A.M. Voorbij. Atherosclerosis 2001; 154: 641-649.
189. Molecular genetics and gene expression in atherosclerosis. P.A. Doevendans, J.W. Jukema, W. Spiering, J.C. Defesche, J.J.P. Kastelein. Int J Cardiol 2001; 80: 161-172.
190. Genetic and metabolic factors predicting risk of cardiovascular disease in familial hypercholesterolemia. T.J. Smilde, S. van Wissen, H. Wollersheim, J.J.P. Kastelein, A.F.H. Stalenhoef. Neth J Med 2001; 59: 184-195.
191. Global perspectives of familial hypercholesterolemia. S.W. Fouchier, J.C. Defesche, J.J.P. Kastelein. Community Genet 2001; 4: 61-67.
192. Genetic aspects of restenosis after percutaneous coronary interventions. Towards more tailored therapy. J.W. Jukema, W.R.P. Agema, S.N. Pimstone, J.J.P. Kastelein. Eur Heart Journal 2001; 22: 2058-2074.
193. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin Genet 2001; 60: 293-300.
194. New role for combination therapy in lipid management. J.J.P. Kastelein and M. van Dam. Br J Cardiol 2001; 8: 639-653.
195. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. A.D. Attie, J.J.P. Kastelein, M.R. Hayden. J Lipid Res 2001; 42: 1717-1726.
196. The molecular basis of familial hypercholesterolemia in The Netherlands. S.W. Fouchier, J.C. Defesche, M.A.W. Umans-Eckenhausen, J.J.P. Kastelein. Hum Genet 2001; 109: 602-615.
197. Nevrivapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. M. van der Valk, J.J.P. Kastelein, R.L. Murphy, F. van Leth, C. Katlama, A. Horban, M. Glesby, G. Behrens, B. Clotet, R.K. Stellato, H.O.F. Molhuizen, R. Reiss. AIDS 2001; 15: 2407-2412.
2002
198. Association between increased arterial wall thickness and impairment in ABCA1 driven cholesterol efflux; an observational study. M.J. van Dam. E. de Groot, S.M. Clee, G.K. Hovingh, R. Roelants, A. Brooks-Wilson, A.H. Zwinderman, A.J. Smit, A.H.M. Smelt, A.K. Groen, M.R. Hayden, J.J.P. Kastelein. Lancet 2002; 359: 37-41.
199. Treatment of hyperlipidemia with the statins: Redefining what the statins can do. M. van Dam, J.J.P. Kastelein,. CVR&R 2002; 23: 77-81.
200. Lipoproteins and Atherosclerosis. J.C. Defesche and J.J.P. Kastelein. In: Cardiavascular Genetics for Clinicians. Eds: P.A. Doevendans and A.A.M. Wilde. Kluwer Academic Publishers 2002; pp. 51-58.
201. Phenotypic variability in familial hypercholesterolaemia: an update. A.C.M. Jansen, S. van Wissen, J.C. Defesche, J.J.P. Kastelein. Current Opinion in Lipidology 2002; 13: 165-171.
202. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158®Cys) homozygotes is associated with hyperinsulinemia. F. de Beer, A.F.H. Stalenhoef, N. Hoogerbrugge, J.J.P. Kastelein, J.A. Gevers Leuven, C.M. van Duijn, L.M. Havekes, A.H.M. Smelt. Arterioscler Thromb Vasc Biol 2002; 22: 294-299.
203. The efficacy and safety of a novel cholesteryl ester transfer protein hinibitor, JTT-705, in humans. A randomized phase II dose-response study. G.J. de Grooth, J.A. Kuivenhoven, A.F.H. Stalenhoef, J. de Graaf, A.H. Zwinderman, J.L. Posma, A. van Tol, J.J.P. Kastelein. Circulation 2002; 105: 2159-2165.
204. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. K.Y. Zwarts, S.M. Clee, A.H. Zwinderman, J.C. Engert, R. Singaraja, O. Loubser, E. James, K. Roomp, T.J. Hudson, J.W. Jukema, J.J.P. Kastelein, M.R. Hayden. Clin Genet 2002; 61: 115-125.
205. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. A.H. Maitland-van der Zee, O.H. Klungel, B.H.Ch. Stricker, W.M.M. Verschuren, J.J.P. Kastelein, H.G.M. Leufkens, A. de Boer. Atherosclerosis 2002; 163: 213-222.
206. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. S. de Jongh, M.R. Lilien, H.D. Bakker, B.A. Hutten, J.J.P. Kastelein, E.S.G. Stroes. Atherosclerosis 2002; 163: 193-197.
207. Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol. M van Dam, S. van Wissen, J.J.P. Kastelein. J. Cardiovasc. Risk 2002; 9: 89-95.
208. Two-year efficacy and safety of simvastatin 80 mg in Familial Hypercholesterolemia (The Examination of Probands and Relatives in Statin Studies with Familial Hypercholesterolemia (ExPRESS FH). P.R.W. de Sauvage Nolting, R.J.A. Buirma, B.A. Hutten and J.J.P. Kastelein, on behalf of the Dutch ExPRESS Investigators Group. Am J Cardiol 2002; 90: 181-184.
209. Long-term efficacy and safety of Atorvastatin in the treatment of severe type III and combined dyslipidemia. M. van Dam, M. Zwart, F. de Beer, A.H.M. Smelt, M.H. Prins, M.D. Trip, L.M. Havekes, P.J. Lansberg, J.J.P. Kastelein. Heart 2002; 88: 234-238.
210. Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease. M.D. Trip, Y.M. Smulders, J.J. Wegman, X. Hu, J.M.A. Boer, J.B. ten Brink, A.H. Zwinderman, J.J.P. Kastelein, E.J.M. Feskens, A.A.B. Bergen. Circulation 2002; 106: 773-775.
211. Parental attitude towards genetic testing for familial hypercholesterolaemia in children. M.A.W. Umans-Eckenhausen, F.J. Oort, K.C.M.P. Ferenschild, J.C. Defesche, J.J.P. Kastelein, J.C.J.M. de Haes. J Med Genet 2002; 39: e49.
212. Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in statin studies with familial hypercholesterolemia (Express FH). P.R.W. de Sauvage Nolting, R.J.A. Buirma, B.A. Hutten, J.J.P. Kastelein, the Dutch Express investigators Group. Atherosclerosis 2002; 164: 347-354.
213. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. A.D. Attie, R.M. Krauss, M.P. Gray-Keller, A. Brownlie, M. Miyazaki, J.J.P. Kastelein, A.J. Lusis, A.F.H. Stalenhoef, J.P. Stoehr, M.R. Hayden, J.M. Ntambi. J. Lipid Res 2002; 43: 1899-1907.
214. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. A randomized, double-blind, placebo-controlled trial with simvastatin. S. de jongh, L. Ose, T. Szamosi, C. Gagne, M. Lambert, R. Scott, P. Perron, D. Dobbelaere, M. Saborio, M.B. Tuohy, M. Stepanavage, A. Sapre, B. Gumbiner, M. Mercuri, P. van Trotsenburg, H.D. Bakker, J.J.P. Kastelein, for the Simvastatin in Children Study Group. Circulation. 2002; 106: 2231-2237.
215. Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low density lipoprotein cholesterol levels. J. de Graaf, P.R.W. de Sauvage Nolting, M.J. van Dam, E.M. Belsey, J.J.P. Kastelein, P.H. Pritchard, A.F.H. Stalenhoef. Brit J Nutrition 2002; 88: 479-488.
216. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. S. van Wissen, M.D. Trip, T.J. Smilde, J. de Graaf, A.F.H. Stalenhoef, J.J.P. Kastelein. Atherosclerosis 2002; 165: 361-366.
217. Truncation mutations in human ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. C.L. Wellington, Y.Z. Yang, S. Zhou, S.M. Clee, B. Tan, K. Hirano, K. Zwarts, A. Kwok, A. Gelfer, M. Marcil, S. Newman, K. Roomp, R. Singaraja, J. Collins, L.H. Zhang, J.J.P. Kastelein, M.R. Hayden. J Lipid Res 2002; 43: 1939-1949.
218. Identification and functional analysis of a naturally occurring E89K mutation in the ABCA1 gene of the WHAM chickens. A.D. Attie, Y. Hamon, A.R. Brooks-Wilson, M. Gray-Keller, M.L.E. MacDonald, V. Rigot, A. Tebon, L.H. Zhang, J. Mulligan, R.R. Singaraja, J.J. Bitgood, M.E. Cook, J.J.P. Kastelein, G. Chimini, M.R. Hayden. J Lipid Res 2002; 43: 1610-1617.
219. Elevated remnant-like particles in heteroygous familial hypercholesterolemia and response to statin therapy. P.R.W. de Sauvage Nolting, M.B. Twickler, G.M. Dallinga-Thie, R.J.A. Buirma, B.A. Hutten, J.J.P. Kastelein, for the ExPRESS study group. Circulation 2002; 106: 788-792.